• 1
    Akdis M. Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol 2006;18:738744.
  • 2
    Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006;6:761771.
  • 3
    Durham SR, Walker SM, Varga E-V, Jacobson MR, O’Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468475.
  • 4
    Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:13921397.
  • 5
    Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251256.
  • 6
    Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel concepts in the pathogenesis, prevention, and treatment of allergic diseases. J Allergy Clin Immunol 2005;116:961968; quiz 969.
  • 7
    Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Muller U et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:16761683.
  • 8
    Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98106.
  • 9
    Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:12051214.
  • 10
    Francis JN, Till SJ, Durham SR. Induction of IL-10+ CD4+ CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:12551261.
  • 11
    Mobs C, Slotosch C, Loffler H, Jakob T, Hertl M, Pfutzner W. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J Immunol 2010;184:21942203.
  • 12
    Yamanaka K, Yuta A, Kakeda M, Sasaki R, Kitagawa H, Gabazza EC et al. Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J Allergy Clin Immunol 2009;124:842845.
  • 13
    Grindebacke H, Larsson P, Wing K, Rak S, Rudin A. Specific immunotherapy to birch allergen does not enhance suppression of Th2 cells by CD4(+)CD25(+) regulatory T cells during pollen season. J Clin Immunol 2009;29:752760.
  • 14
    O’Hehir RE, Gardner LM, de Leon MP, Hales BJ, Biondo M, Douglass JA et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009;180:936947.
  • 15
    Jones SM, Pons L, Roberts JL, Scurlock AM, Perry TT, Kulis M et al. Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 2009;124:292300.
  • 16
    Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008;121:14671472.
  • 17
    Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:32523259.
  • 18
    Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007;178:46584666.
  • 19
    Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J et al. Relation of CD4+ CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004;363:608615.
  • 20
    Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, De Vries JE et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737742.
  • 21
    Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:15671575.
  • 22
    Akdis CA, Kussebi F, Pulendran B, Akdis M, Lauener RP, Schmidt-Weber CB et al. Inhibition of T helper 2-type responses, IgE production and eosinophilia by synthetic lipopeptides. Eur J Immunol 2003;33:27172726.
  • 23
    Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775787.
  • 24
    Izcue A, Hue S, Buonocore S, Arancibia-Carcamo CV, Ahern PP, Iwakura Y et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 2008;28:559570.
  • 25
    Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:12371240.
  • 26
    Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Induction of circulating myelin basic protein and proteolipid protein- specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996;98:7077.
  • 27
    Akdis CA, Blaser K. IL-10 induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999;13:603609.
  • 28
    Klunker S, Chong MM, Mantel PY, Palomares O, Bassin C, Ziegler M et al. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J Exp Med 2009;206:27012715.
  • 29
    Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011;127:701721.
  • 30
    Deniz G, Erten G, Kucuksezer UC, Kocacik D, Karagiannidis C, Aktas E et al. Regulatory NK cells suppress antigen-specific T cell responses. J Immunol 2008;180:850857.
  • 31
    Zhou J, Appleton SE, Stadnyk A, Lee TD, Nashan BA. CD8(+)gammadelta T regulatory cells mediate kidney allograft prolongation after oral exposure to alloantigen. Transpl Int 2008;21:679687.
  • 32
    Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644651.
  • 33
    Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-g secretion in specific allergen stimulated T cell cultures. J Immunol 1995;154:41784194.
  • 34
    Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:13561365.
  • 35
    Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008;205:28872898.
  • 36
    Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009;39:17861800.
  • 37
    Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001;108:18651873.
  • 38
    Osna N, Elliott K, Khan MM. Regulation of interleukin-10 secretion by histamine in TH2 cells and splenocytes. Int Immunopharmacol 2001;1:8596.
  • 39
    Kunzmann S, Mantel P-Y, Wohlfahrt J, Akdis M, Blaser K, Schmidt-Weber C. Histamine enhances TGF-beta1-mediated suppression of Th2 responses. FASEB J 2003;17:10891095.
  • 40
    Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OAR, Malolepszy J et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001;413:420425.
  • 41
    Müller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific- allergen immunotherapy. J Allergy Clin Immunol 2001;107:8186.
  • 42
    Jutel M, Zak-Nejmark T, Wrzyyszcz M, Malolepszy J. Histamine receptor expression on peripheral blood CD4+ lymphocytes is influenced by ultrarush bee venom immunotherapy. Allergy 1997;52(Suppl. 37):88.
  • 43
    Muller UR, Jutel M, Reimers A, Huber K, Kriegel C, Steiner U et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honey bee venom immunotherapy: a double blind placebo controlled study. J Allergy Clin Immunol 2008;122:10011007.
  • 44
    Jutel M, Akdis CA. T-cell subset regulation in atopy. Curr Allergy Asthma Rep 2000;11:139145.
  • 45
    Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:47724780.
  • 46
    Wu K, Bi Y, Sun K, Xia J, Wang Y, Wang C. Suppression of allergic inflammation by allergen-DNA-modified dendritic cells depends on the induction of Foxp3+ regulatory T cells. Scand J Immunol 2008;67:140151.
  • 47
    Bellinghausen I, Brand U, Steinbrink K, Enk AH, Knop J, Saloga J. Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: differences from hydrocortisone-treated dendritic cells. J Allergy Clin Immunol 2001;108:242249.
  • 48
    Kearley J, Barker JE, Robinson DS, Lloyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+ CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med 2005;202:15391547.
  • 49
    Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008;63:14551463.
  • 50
    Gri G, Piconese S, Frossi B, Manfroi V, Merluzzi S, Tripodo C et al. CD4+ CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40–OX40L interaction. Immunity 2008;29:771781.
  • 51
    Kearley J, Robinson DS, Lloyd CM. CD4+ CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol 2008;122:617624.
  • 52
    Burchell JT, Wikstrom ME, Stumbles PA, Sly PD, Turner DJ. Attenuation of allergen-induced airway hyperresponsiveness is mediated by airway regulatory T cells. Am J Physiol Lung Cell Mol Physiol 2009;296:L307L319.
  • 53
    Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2000;127:1827; quiz 28-9.
  • 54
    Golden DB, Meyers DA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Clinical relevance of the venom-specific immunoglobulin G antibody level during immunotherapy. J Allergy Clin Immunol 1982;69:489493.
  • 55
    Müller UR, Helbling A, Bischof M. Predictive value of venom-specific IgE, IgG and IgG subclass antibodies in patients on immunotherapy with honey bee venom. Allergy 1989;44:412418.
  • 56
    van der Giessen M, Homan WL, van Kernbeek G, Aalberse RC, Dieges PH. Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy. Int Arch Allergy Appl Immunol 1976;50:625640.
  • 57
    Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005;116:608613.
  • 58
    Reisinger J, Horak F, Pauli G, van Hage M, Cromwell O, Konig F et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005;116:347354.
  • 59
    Rossi RE, Monasterolo G. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Int Arch Allergy Immunol 2004;135:4453.
  • 60
    van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, Arnved J et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999;163:29442952.
  • 61
    Kehry MR, Yamashita LC. Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing. Proc Natl Acad Sci USA 1989;86:75567560.
  • 62
    Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002;105:919.
  • 63
    van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007;317:15541557.
  • 64
    Jakobsen CG, Bodtger U, Kristensen P, Poulsen LK, Roggen EL. Isolation of high-affinity human IgE and IgG antibodies recognising Bet v 1 and Humicola lanuginosa lipase from combinatorial phage libraries. Mol Immunol 2004;41:941953.
  • 65
    Jakobsen CG, Bodtger U, Poulsen LK, Roggen EL. Vaccination for birch pollen allergy: comparison of the affinities of specific immunoglobulins E, G1 and G4 measured by surface plasmon resonance. Clin Exp Allergy 2005;35:193198.
  • 66
    Aalberse RC, Platts-Mills TA. How do we avoid developing allergy: modifications of the TH2 response from a B-cell perspective. J Allergy Clin Immunol 2004;113:983986.
  • 67
    Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007;120:688695.
  • 68
    Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006;6:741750.
  • 69
    Rak S, Lowhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients. J Allergy Clin Immunol 1988;82(3 Pt 1):470480.
  • 70
    Hakansson L, Heinrich C, Rak S, Venge P. Priming of eosinophil adhesion in patients with birch pollen allergy during pollen season: effect of immunotherapy. J Allergy Clin Immunol 1997;99:551562.
  • 71
    Rak S, Hakanson L, Venge P. Immunotherapy abrogates the generation of eosinophil and neutrophil chemotactic activity during pollen season. J Allergy Clin Immunol 1990;86:706713.
  • 72
    Pierkes M, Bellinghausen I, Hultsch T, Metz G, Knop J, Saloga J. Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells. J Allergy Clin Immunol 1999;1:326332.
  • 73
    Shim YK, Kim BS, Cho SH, Min KU, Hong SJ. Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin Exp Allergy 2003;33:5257.
  • 74
    Schandane L, Alonso-Vega C, Willems F, Gerard C, Delvaux A, Velu T et al. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10. J Immunol 1994;152:43684374.
  • 75
    Palaniyandi SS, Watanabe K, Ma M, Tachikawa H, Kodama M, Aizawa Y. Inhibition of mast cells by interleukin-10 gene transfer contributes to protection against acute myocarditis in rats. Eur J Immunol 2004;34:35083515.
  • 76
    Nieminen K, Valovirta E, Savolainen J. Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy. Pediatr Allergy Immunol 2009;21:e174184.
  • 77
    Ley K, Smith E, Stark MA. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res 2006;34:229242.